Weight Management Treatments for Obesity
Trial Summary
Yes, you will need to stop taking your GLP-1 medication (like Wegovy, Ozempic, Mounjaro, or Zepbound) to participate in this trial. The trial is specifically for those who are willing to discontinue these medications.
Research shows that the combination of naltrexone and bupropion, known as Contrave, leads to significant weight loss in obese adults when combined with lifestyle changes. In several studies, participants lost an average of 11-22 pounds (5-9 kg) over a year, and there were improvements in health markers related to heart and metabolism.
12345Naltrexone and bupropion, used together for weight management, have been generally well tolerated in clinical trials, with nausea being the most common side effect. These trials showed that the combination is safe for use in adults who are obese or overweight with related health issues.
13456Naltrexone/bupropion is unique because it combines two medications, naltrexone and bupropion, to help with weight loss and maintenance, especially in adults who are obese or overweight with related health issues like diabetes or high blood pressure. This combination works by affecting the brain's reward system and appetite control, and it is used alongside lifestyle changes such as diet and exercise.
23456Eligibility Criteria
This trial is for individuals who have been using semaglutide or tirzepatide for obesity but are stopping these medications. Participants should be adults looking to manage their weight post-discontinuation.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive behavioral or lifestyle support from WW Clinic with or without medications for weight management
Follow-up
Participants are monitored for safety and effectiveness after treatment